Wiley Editing Services

There should be no barriers to getting your research published, yet we know that manuscripts are often returned for English language and formatting issues. Let Wiley Editing Services provide you with expert help to ensure your paper is ready for submission.

Don’t be rejected. Get published.

English Language Editing
Avoid English language errors
Get direct access to native English speakers who are experts in your field, providing extensive edits for language and style.

Manuscript Formatting
Save valuable time formatting to a specific journal style
Skilled formatters will ensure your manuscript and references are formatted according to the style guide of your chosen journal.

Translation Service
Let your research do the talking
Receive accurate, high quality translation from Chinese, Spanish and Portuguese by academics with advanced degrees.

Figure Preparation
Improve the visual presentation of your research
We generate publication-ready figures, tables and diagrams set to your chosen journal’s specified size, resolution and layout.

Journal Recommendation
Make an informed decision
We will match your paper with 3-5 carefully selected journals from a range of publishers that match your topic and publication goals.

wileyeditingservices.com
HAEMOPHILIA  Volume 26, Issue 1, January 2020

Contents

Review Articles
6 Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline
E. Gray, S. Kitchen, A. Bowyer, P. Chowdary, P. V. Jenkins, P. Murphy, S. Platton, A. Riddell and W. Lester

17 Achieving the unimaginable: Health equity in haemophilia

25 Fibrinogen concentrates in hereditary fibrinogen disorders: Past, present and future
A. Casini and P. de Moerloose

33 Characteristics and management of the haemophilia-associated pseudotumours
A. J. Doyle, D. L. Back and S. Austin

Original Articles

Clinical haemophilia

41 Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
P. T. Ebbert, F. Xavier, C. D. Seaman and M. V. Ragni

47 SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

56 Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users
A. McEneny-King, C. H. Yeung, A. N. Edginton, A. Iorio and S. E. Croteau

64 Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
H. Yaish, T. Matsushita, M. Belhani, V. Jiménez-Yuste, K. Karakli, L. Korsholm, I. Matytsina, C. Philipp, K. Reichwald and R. Wu

73 Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool
M. Carcao, L. Zunino, N. L. Young, S. Dover, V. Boukili, P. Hilliard, V. E. Price and V. S. Blanchette

79 Inhibitor epidemiology and genetic-related risk factors in people with haemophilia from Côte d’Ivoire
C. Lambot, N. Lamoë, N. Meité, I. Sango, S. Eeckhoudt and C. Hermans

86 Positive emotions despite substantial burden: The alchemy of haemophilia caregiving
C. E. Schwartz, R. B. Stark, B. D. Stucky, W. Michael and B. D. Rapkin
Von Willebrand disease
von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage

Women with bleeding disorders
An international survey to inform priorities for new guidelines on von Willebrand disease
M. A. Kalot, M. Al-Khatib, N. T. Connell, V. Flood, R. Brignardello-Petersen, P. James and R. A. Mustafa

Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?
S. Raso, C. Lambert, A. Boban, M. Napolitano, S. Siragusa and C. Hermans

Bleeding assessment in haemophilia carriers—High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China
S. Li, Y. Fang, L. Li, A. Lee, M.-C. Poon, Y. Zhou, X. Zhang, S. Wang, Y. Cheng and K. Li

Musculoskeletal
Age-related severity and distribution of haemophilic arthropathy of the knee, ankle and elbow among Chinese patients with haemophilia

Chromic phosphate-32 colloid radiosynovectomy for the treatment of haemophilic synovitis: A long-term follow-up study
A. Ebrahimpour, M. Ebrahiminasab, M. Kaseh, S. Asadollahi and S. J. Mortazavi

Rhenium-188 radiosynovectomy for chronic haemophilic synovitis: Evaluation of its safety and efficacy in haemophilic patients

Laboratory science
Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline
P. V. Jenkins, A. Bowyer, C. Burgess, E. Gray, S. Kitchen, P. Murphy, S. Platton, A. Riddell, P. Choudary and W. Lester

An overview of turoctocog alfa pegol (N8-GP; ESPEROCT®) assay performance: Implications for postadministration monitoring
M. Ezban, M. Hansen and M. Kjalke

Rotational thromboelastometry can predict the probability of bleeding events in a translational rat model of haemophilia A following gene-based FVIIa prophylaxis
Online Supplement

The articles listed below are available as an online supplement to this volume and issue at:
http://www.wileyonlinelibrary.com/journal/hae

Letters to the Editor

e1 Patient profile, clinical characteristics and treatment response in acquired haemophilia A: A retrospective analysis of a single-centre experience over a 3-year period
A. F. Abdalkader, A.-M. Salih and E. K. Ibraheem

e5 ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

e9 Sleeve gastrectomy in haemophilia type A: Reducing the costs of prophylaxis
R. H. Arias, J. P. Vélez, J. Ramirez and C. E. Ocampo

e11 PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety
A. Baumann

e14 Maternal and neonatal outcomes in carriers of haemophilia A and B: A Swedish Medical Birth Register study
A. Olsson, V. Radulovic and U.-B. Wennerholm

e18 Prophylactic vs episodic treatment to prevent bleeds and preserve joint function in Thai children with moderate and severe haemophilia A
R. Songnuy, P. Seksarn and D. Soonthikul

e21 Novel treatment of combined factor V and factor VIII deficiency with Factor Eight Inhibitor Bypass Activity
O. Olaiya, L. E. Amos and S. L. Carpenter

e23 Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series
B. Kleiboer, B. Nielsen, A. D. Ma, Y. Abajas, D. M. Monroe and N. S. Key

e26 A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants
R. Deshpande, S. Shanbhag, A. Jadli and S. Shetty

e28 Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products
A. B. Payne, D. Ellingsen, J. Driggers, C. J. Bean and C. H. Miller